News

Public · Published

Citigroup maintains Eli Lilly at Buy, raises price target to $1650 from $1600

Citigroup kept its Buy rating on Eli Lilly and raised its price target to $1650 from $1600, a 3.1% increase. That target implies 16.4% upside from the October 30 close of $1417.54.

Published:

Updated:

What happened

Citigroup kept its Buy rating on Eli Lilly and raised its price target to $1650 from $1600, a 3.1% increase. That target implies 16.4% upside from the October 30 close of $1417.54.

Confirmed

Global impact / market context

A higher price target from a major bank can signal analysts expect more profit growth ahead, which may draw buyer interest and support the share price. It can also shape how investors judge Eli Lilly against other drugmakers.

Analyst inference

Other recent analyst notes on Eli Lilly carry targets from $1500 to $1612, all above the stock's close. Citigroup's $1650 sits at the top of that range, suggesting its view is more optimistic than peers.

Analyst inference

What to watch

  1. Citigroup raised its Eli Lilly price target to $1650 from $1600 while keeping a Buy rating, a 3.1% increase that implies 16.4% upside from the October 30 close of $1417.54. Confirmed
  2. Watch whether other analysts follow Citigroup and raise their own Eli Lilly price targets above the recent $1500 to $1612 range, which would suggest a broader upgrade in expectations. Proposed
  3. Watch Eli Lilly's spending on research and new factories, since higher costs could slow profit growth and make it harder for the stock to reach Citigroup's $1650 target. Analyst inference

Evidence

  • Original source link unavailable